Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Kalos

Showing results (71-80 of 76) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 76 results.
Cancer Immunology Research|September 3, 2020
Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor ImmunityHelen Kotanides, Yiwen Li, Maria Malabunga, et al.
Journal for Immunotherapy of Cancer|March 17, 2016
Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trialsHolbrook E Kohrt, Paul C Tumeh, Don Benson, et al.
Science Translational Medicine|August 9, 2013
Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cellsBrian J Cameron, Andrew B Gerry, Joseph Dukes, et al.
Nature Medicine|May 8, 2012
Monoclonal TCR-redirected tumor cell killingNathaniel Liddy, Giovanna Bossi, Katherine J Adams, et al.
Nature Medicine|July 21, 2015
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myelomaAaron P Rapoport, Edward A Stadtmauer, Gwendolyn K Binder-Scholl, et al.
Nature|June 1, 2018
Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cellsJoseph A Fraietta, Christopher L Nobles, Morgan A Sammons, et al.
Pageof 8

Showing results (71-80 of 76) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 76 results.
Cancer Immunology Research|September 3, 2020
Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor ImmunityHelen Kotanides, Yiwen Li, Maria Malabunga, et al.
Journal for Immunotherapy of Cancer|March 17, 2016
Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trialsHolbrook E Kohrt, Paul C Tumeh, Don Benson, et al.
Science Translational Medicine|August 9, 2013
Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cellsBrian J Cameron, Andrew B Gerry, Joseph Dukes, et al.
Nature Medicine|May 8, 2012
Monoclonal TCR-redirected tumor cell killingNathaniel Liddy, Giovanna Bossi, Katherine J Adams, et al.
Nature Medicine|July 21, 2015
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myelomaAaron P Rapoport, Edward A Stadtmauer, Gwendolyn K Binder-Scholl, et al.
Nature|June 1, 2018
Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cellsJoseph A Fraietta, Christopher L Nobles, Morgan A Sammons, et al.
Pageof 8